Search results
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Zacks via Yahoo Finance· 5 days agoData from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a...
Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Thursday
ETF DAILY NEWS· 7 hours agoSage Therapeutics (NASDAQ:SAGE – Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, April 25th. Sage Therapeutics (NASDAQ:SAGE – Get Free Report ...
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbush
ETF DAILY NEWS· 5 days agoWedbush reiterated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $24.00 price ...
Scotiabank Trims Sage Therapeutics (NASDAQ:SAGE) Target Price to $19.00
ETF DAILY NEWS· 2 days agoSage Therapeutics (NASDAQ:SAGE – Free Report) had its target price decreased by Scotiabank from $34.00 to $19.00 in a research note issued to investors on Thursday, Benzinga reports. Scotiabank ...
Sage Therapeutics (NASDAQ:SAGE) Downgraded to “Underperform” at Bank of America
ETF DAILY NEWS· 5 days agoBank of America downgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a neutral rating to an underperform rating in a research note released on Wednesday, Marketbeat Ratings ...
Wedbush Weighs in on Sage Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:SAGE)
ETF DAILY NEWS· 3 days agoSage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Analysts at Wedbush reduced their Q1 2024 earnings estimates for Sage Therapeutics in a research note issued to investors on Wednesday, ...